10-Q: Silence Therapeutics Reports Q1 2025 Financial Results and Provides Business Update

Silence Therapeutics reports a net loss of $28.53 million for Q1 2025, with a focus on advancing clinical trials and seeking partnerships.

Summary

• Silence Therapeutics plc reported a net loss of $28.53 million for the three months ended March 31, 2025, compared to a net loss of $2.31 million for the same period in 2024.
• Revenue decreased significantly to $0.14 million from $15.7 million in the prior year, primarily due to lower research collaboration income from AstraZeneca.
• Research and development expenses increased to $20.81 million from $11.85 million, driven by the advancement of clinical trials.
• The company's cash, cash equivalents, and short-term investments totaled $136.5 million as of March 31, 2025.
• Silence Therapeutics believes its current resources are sufficient to fund operations into 2028, including anticipated milestone payments of $20 million over the next three years.
• The company is progressing its divesiran and zerlasiran programs, with ongoing Phase 2 and Phase 3 readiness activities, respectively.
• Partnering discussions for potential Phase 3 development of zerlasiran are ongoing.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company reported a significant loss and decreased revenue, it has sufficient funding to continue operations into 2028 and is making progress with its clinical programs. The ongoing partnering discussions for zerlasiran are also a positive sign.

Positives

• The company believes its current cash and cash equivalents are sufficient to fund its operating expenses for at least the next twelve months.
• Divesiran has received Fast Track and orphan drug designations from the FDA for PV.
• Divesiran has received orphan drug designation from the European Commission for PV in Europe.
• Positive regulatory feedback has been received from the FDA and EMA on the Phase 3 cardiovascular outcomes study design for zerlasiran.
• The company is engaged in global partnership discussions to seek a third-party partner for potential Phase 3 development of zerlasiran.

Negatives

• The company reported a significant net loss of $28.53 million for Q1 2025.
• Revenue decreased substantially to $0.14 million compared to $15.7 million in the same period last year.
• The company has incurred recurring losses since inception.
• Hansoh notified Silence Therapeutics that it will not pursue further development under the Hansoh collaboration.

Risks

• The company's future funding requirements will depend on various factors, including the scope and cost of clinical trials, the extent of success in research programs, and the outcome of regulatory approvals.
• The company is subject to stringent and evolving U.S. and foreign data privacy and security laws, regulations, contractual obligations, industry standards, policies, and other obligations, and our (or the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class actions); fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.
• The company may face challenges in obtaining future funding, which could impact its financial condition and ability to pursue its business strategies.
• The company's success depends on the successful development and commercialization of its product candidates, which is highly uncertain.

Future Outlook

Silence Therapeutics believes its current cash, cash equivalents, and treasury instruments will be sufficient to fund its anticipated operating and capital expenditure requirements into 2028, which includes receipt of anticipated milestones from collaboration agreements of $20 million in the next three years. The company is progressing its divesiran and zerlasiran programs, with ongoing Phase 2 and Phase 3 readiness activities, respectively. Partnering discussions for potential Phase 3 development of zerlasiran are ongoing.

Management Comments

• We advanced enrollment into the Phase 2 portion of the SANRECO study of divesiran in PV patients and remain on-track to complete enrollment by year-end 2025.
• We advanced core Phase 3 readiness activities for our zerlasiran program, including manufacturing and supply scale-up, which remain on-track to complete by mid-2025.
• Partnering discussions for potential Phase 3 development are ongoing.

Industry Context

Silence Therapeutics is operating in the competitive RNA therapeutics field, focusing on siRNA technology. The company's progress with divesiran and zerlasiran, along with its collaboration with AstraZeneca, positions it to address unmet needs in cardiovascular disease, hematology, and rare diseases. The ongoing partnering discussions for zerlasiran reflect the industry trend of collaboration for late-stage development and commercialization.

Comparison to Industry Standards

• Silence Therapeutics' focus on siRNA therapeutics aligns with the broader industry trend of developing targeted therapies for various diseases.
• Companies like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals are also key players in the RNAi therapeutics space.
• Silence Therapeutics' collaboration with AstraZeneca is similar to other partnerships in the industry, where larger pharmaceutical companies collaborate with smaller biotech firms to leverage their expertise and technology.
• The company's cash runway into 2028 is relatively strong compared to other biotech companies of similar size, providing financial stability for ongoing clinical development programs.
• The pursuit of orphan drug designations for divesiran is a common strategy in the rare disease space to incentivize drug development and secure market exclusivity.

Stakeholder Impact

• Shareholders: The net loss and decreased revenue may negatively impact shareholder value in the short term, but the company's long-term prospects depend on the success of its clinical programs and partnerships.
• Employees: The company's financial stability and ongoing clinical programs provide job security for employees.
• Customers: The development of divesiran and zerlasiran could provide new treatment options for patients with PV and high Lp(a), respectively.
• Partners: The company's collaborations with AstraZeneca and potential future partners are crucial for the development and commercialization of its product candidates.

Next Steps

• Complete enrollment in the Phase 2 portion of the SANRECO study of divesiran by year-end 2025.
• Complete core Phase 3 readiness activities for zerlasiran by mid-2025.
• Continue partnering discussions for potential Phase 3 development of zerlasiran.
• Advance the Phase 1 study of SLN312 (licensed to AstraZeneca).

Key Dates

Keywords

siRNA, therapeutics, divesiran, zerlasiran, clinical trials, mRNAi GOLD platform, AstraZeneca, collaboration, financial results, Silence Therapeutics